Background: Early treatment ensures optimal outcomes in rheumatoid arthritis (RA) 
Introduction
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory disease that affects 1.8% of the Australian population and causes significant morbidity and mortality. 1 The early initiation of disease-modifying anti-rheumatic drugs (DMARD) is associated with improved clinical and radiographic outcomes. 2 Evidence has emerged that the early stage of RA is pathologically distinct, and RA may be more responsive to treatment at this early time. 3 This therapeutic window is frequently cited as 12 weeks from symptom onset; however, recent evidence suggests a longer window may exist. [4] [5] [6] [7] Delay in presentation can be broadly considered to be patient delays, such as seeking care from a general practitioner (GP) (delay 1), GP delays in conducting investigations and determining that the patient requires referral (delay 2) and rheumatologist delays in being appropriately triaged and reviewed, for instance, at an early arthritis clinic (EAC) (delay 3). Further subdivisions have been made in previous studies, but these have not been found to be relevant. 8 As EAC are protocol-driven to commence disease-modifying treatment in appropriate patients immediately on diagnosis, delays at this point have been found to be negligible. [9] [10] [11] This study aimed to quantify patient delay in Australian patients presenting to an EAC with new-onset RA and to explore factors that influenced delay and resultant patient outcomes.
Methods
This study involved patients who first attended the EAC of Princess Alexandra Hospital in Australia between 2008 and 2015 who met the RA ACR 1987 or 2010 ACR/EULAR classification criteria; had baseline data available and attended at least one follow-up visit at 3 months (10-14 weeks), 6 months (21-31 weeks) or 12 months (47-57 weeks). Patient charts were reviewed retrospectively to determine the date of symptom onset (as reported by the patient on a written baseline questionnaire), initial presentation to their GP (according to information obtained from GP referral or as self-reported by the patient in their history) and the date of GP referral.
Demographic data were obtained by patient questionnaire and included age, self-reported date of symptom onset, highest level of highest education achieved (primary, secondary or tertiary level) and smoking status. Socioeconomic status (SES) was estimated by postcode using the Australian Bureau of Statistics Postal Area Index of Relative Socioeconomic Advantage and Disadvantage based on 2011 census data, with each patient assigned according to a decile [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] of relative advantage/ disadvantage. 12 Clinical and laboratory data were entered into a clinic database at each patient visit, including rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA) status; C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR); patient-assessed visual analogue scores (VAS) for pain, disease activity and fatigue (0-100 mm); a physician global assessment (0-100 mm); modified Health Assessment Questionnaire score (mHAQ); tender joint count (TJC) and swollen joint count (SJC). Finally, the Disease Activity Score (DAS28-ESR), hereafter called DAS28, incorporating tender and swollen 28-joint counts, and ESR and patient disease activity VAS were calculated.
Local Research Ethics Committee approval (Metro South Hospital and Health Service and The University of Queensland) was granted to collect and analyse the data retrospectively.
For statistical analysis continuous data were presented as mean and standard deviation (SD) or as median and interquartile range (IQR), depending on the data distribution, and categorical variables were presented as a percentage. For baseline factors affecting patient delay, we removed features with missing values above 25%. Variables considered in analysis included: age, gender, ever smoked, anti-CCP and RF positivity, SES, education, DAS28, mHAQ, TJC, SJC, serum CRP and ESR, and VAS of patient disease activity, fatigue and pain. The rfImpute function in randomForest package in R (R Foundation for Statistical Computing version 3.4.1) was used to impute missing values. For continuous features, randomForest calculated the weighted average of the non-missing observations using proximity matrix, whereas for categorical features, the imputed value was calculated by finding the category with the largest average proximity. Subsequently, we pre-filtered the 10 most informative features that explain the outcome. We then performed step-wise linear regression to find the best model to predict outcome. The primary measure of clinical outcome was change in DAS28 at subsequent reviews, which was analysed using two-way analysis of variance followed by Tukey's post-hoc multiple comparisons test. Standard statistical analysis was performed using GraphPad Prism version 7.02.
Results

Demographics
A total of 1193 new patients was seen at the EAC between 2008 and 2015, and 135 met the RA ACR 1987 or 2010 ACR/EULAR classification criteria and had baseline and follow-up data, including adequate referral data, available. Adequate data for analysis were available for 88 patients and complete delay components for 75 patients. Table 1 shows patient characteristics at baseline.
Components of delay
Median total delay from symptom onset to assessment by a rheumatologist at the EAC was 26.4 weeks (n = 75). Median patient, GP and rheumatologist delay was 8.7, 4.0 and 8.4 weeks respectively (Table 2); 11.4% (n = 10) of patients were seen within the frequently cited 12-week window post-symptom onset and 17% (n = 14) within a more conservative 16 weeks.
Predictors of delay
Using step-wise linear regression analysis, the most important feature predicting overall delay was the patient presenting to their GP (P = <0.001), with delay in GP referral also being significant (P = <0.001). Rheumatologist delay was not significant in predicting overall delay (P = 0.110) ( Table 3) .
Greater overall delay was predicted by lower DAS28, lower fatigue score and increased TJC. Features predicting increased patient delay included lower DAS28, lower fatigue and lower SES, whereas features predicting increased GP delay were lower DAS28 and increased TJC and ESR (Table 4) . Median SES was in the fifth decile (IQR second to eight), suggesting a reasonable spread of SES among our cohort (data not shown). Given that DAS28 is a composite score of other variables, additional analyses performed excluding DAS28 found that overall delay was significantly associated with fatigue alone (P = 0.021).
Association of delay with outcome
DAS28 was assessed at baseline, 3 and 6 months in patients grouped according to overall delay of <16, 16-24 and >24 weeks respectively. A cumulative reduction in disease activity score at both 3-and 6-month follow-up visits was demonstrated in patients who had been reviewed at the EAC within 16 weeks (Fig. 1) . A total of 39 patients had paired data, with DAS28 recorded at both baseline and 6 months. At 6 months, paired data showed that 80% (n = 5) of patients seen within 16 weeks of symptom onset achieved clinical remission (DAS28 < 2.6), compared to 63% (n = 8) if 16-24 weeks and 38% (n = 26) if greater than 24 weeks.
Discussion Overall delay
The total delay of 26.4 weeks from symptom onset to rheumatology review at an EAC in this Australian study is consistent with published data, primarily from the UK, Europe and Canada, with ranges from 18.4 to 27.5 weeks 5,9,11,13-15 (Table 5 ). Fewer than one in five (17%) patients were seen within the 3-4-month window of opportunity defined in this study, which is slightly lower than internationally published rates ranging from 20% to 31%. 5, 9, 10, 14, 16, 17 Previous studies have variously linked increased delay in diagnosis and/or treatment to age, gender, ethnicity, comorbidities, education, SES, family history of RA, clinical parameters of joint involvement, acute-phase reactants and serology results. 10, [16] [17] [18] [19] [20] This study identifies disease activity, fatigue scores and TJC as predictors of overall delay to EAC review.
Patient delay
This study confirms the experience of other EAC worldwide -that patient delay predominantly contributes to overall delay, 9, 16, 19, [21] [22] [23] although this is not universal. 5, 24 We found that lower DAS28 and fatigue scores at baseline predicted a greater patient delay, possibly reflecting a more insidious onset of disease. This is consistent with previous quantitative 5, 22 and qualitative 25 studies. When DAS28 was excluded from analysis, key aspects of its components (TJC, SJC and patient disease activity VAS) approached but did not independently reach statistical significance (data not shown). Relative socioeconomic disadvantage was additionally associated with longer patient delay in this study, similar to previous findings, despite universal healthcare access in Australia. 18, 26 Previous studies provide insight into how SES may impact health-seeking behaviour, with low levels of health literacy affecting the ability of patients to assess appropriately new symptoms and seek help promptly. 21 An unexpected association was that this study found higher TJC to be associated with greater patient delay. Tenderness can be a vague symptom and is often put down to 'everyday aches and pains', 27 and use of overthe-counter medications to treat more vague symptoms associated with RA can lead to delayed diagnosis and definitive treatment. 28 In our cohort, we considered that patients may have dismissed more widespread joint involvement as general musculoskeletal pain and delayed seeking care. However, this is in contrast to previous studies suggesting that TJC has a positive association with a shorter delay 17, 18 or no association with delay. 4, 9 In addition, patients with milder or intermittent symptoms may be more likely to miss their first EAC appointment after prompt GP referral.
As the greatest contributor to, and predictor of, overall delay, strategies that aim to reduce patient delay are likely to be the most effective in reducing overall delay. Previous research into help-seeking behaviour in early RA can inform future health interventions. 29 This includes the importance of educating the public as to how inflammatory arthritis differs from osteoarthritis Patients seen at the early arthritis clinic (EAC) within 16 weeks had greater improvement in DAS28 and probability of remission at 6 months. DAS28 was recorded at baseline, 3 and 6 months in patient groups of overall delay of <16, 16-24 and >24 weeks. Change in DAS28 at intervals was analysed using two-way analysis of variance followed by Tukey's post-hoc multiple comparisons test.
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and other musculoskeletal symptoms, involving pharmacists at the point where patients seek to self-manage symptoms, and that effective treatments for RA are available and early treatment reduces risk of long-term joint damage and disability. 29 A novel approach recently described in the literature is the use of internet-based screening, for example, through a consumer arthritis website, to find at-risk patients through an early RA screening questionnaire. 30 
GP delay
In this cohort, the delay in investigation and decision to refer to a rheumatologist by the GP (4 weeks) was the smallest contributor to overall delay, consistent with median delays of 2-4 weeks in other similar studies. 9, 13, 16 Lower disease activity (DAS28) and higher ESR and TJC were associated with longer GP delay. Again, this suggests that a more insidious disease onset process and nonspecific markers of inflammation and musculoskeletal pain may lead to the consideration of alternative diagnoses ahead of RA and subsequently delayed rheumatology referral. GP have previously self-reported potential causes of delayed referral in early RA. These include the symptoms of early RA being insufficiently clear, the timeintensive nature of examining the condition, a lack of selfconfidence in the condition, diagnostic uncertainty and inconclusive tests, low RA incidence in the community and confusion with other rheumatic diseases, such as osteoarthritis and gout. 31 Although patient delay exerted the largest influence on overall delay, GP delay did independently predict overall delay in this cohort. Therefore, a continued focus on strategies to reduce GP delay is important and would provide overall benefit in terms of delay reduction.
Rheumatology delay
Delay in rheumatology review is predominantly influenced by local health systems and, given the EAC setting in this study, were expected to be low. 32 While it does not independently predict overall delay, the delay of 8.4 weeks from referral to rheumatology review is greater than most comparable settings overseas, 5, 13, 16 although the Berlin and Prague centres in Raza et al. 13 reported delays in rheumatology assessment of up to 10 weeks. Potential administrative issues include the additional step involved in a central referral hub forwarding incoming referrals to rheumatology; the process of appropriate and timely triage of referrals by a rheumatologist, including whether adequate information was contained in the original referral; and clinic scheduling. An important factor feeding into patient delay is failure to attend the first scheduled appointment. This may be more likely at a weekly specialist clinic than in a setting with a range of appointment options and in patients of lower SES who face a range of logistic challenges to attend or reschedule. Previous research has found that referrals often lack important prognostic data, with strategies proposed to improve this including GP education sessions with the associated distribution of referral guidelines and encouraging rheumatologists to use prognostic factors present in GP referrals for triage. 33 Demonstrated effective strategies to improve outpatient referrals include dissemination of guidelines with structured referral sheets and involvement of consultants in educational activities, whereas passive dissemination of local referral guidelines and feedback of referral rates may not be effective. 34 
Association of delay with outcome
The concept that early treatment improves outcome is well recognised, although the exact nature of this relationship remains unclear. 7, 35 A recent systematic literature review concluded that, even when the heterogeneity of patients is taken into account, prolonged symptom duration prior to treatment is associated with radiographic progression and a lower chance of DMARD-free sustained remission. 2 Nell et al. used DAS28 remission (<2.6) as the primary outcome measure in their case-controlled study, finding that remission was significantly more likely to occur in very early RA (median disease duration 3 months) compared to lateearly RA (median disease duration 12 months). 4 A more recent study also used DAS28 as its primary outcome measure and found that DMARD treatment within 3 months predicted remission. 36 This study adds to the evidence by demonstrating that, in our cohort, an overall delay from symptom onset to attending an EAC of less than 16 weeks resulted in a statistically significant reduction in disease activity and a higher percentage of patients in remission at 6 months.
Limitations
As a retrospective chart review and database interrogation, this study relies on the collection of data partly from within medical charts, a process prone to various sources of error. 37 Absent data required patients to be excluded from this study, variables to be excluded from analysis and for data to be imputed during analysis. We used randomForest imputation to address this as it has been demonstrated as accurate in imputing complex epidemiologic datasets in which some patients have missing data. 38 Second, the date of onset of patient symptoms relies on the accurate recollection of the patient, which may be difficult to reconstruct and may result in recall bias. 9 Due to difficulty in accurately collecting the date the patient presented to his or her GP, only 75 of 135 suitable patients could be included. The data may therefore be biased against RA patients with a more complex presentation of their disease. In addition, this study only considered those patients who presented through their GP. While GP act as 'gate-keepers' to specialist care in Australia and therefore form the bulk of referrals, other routes, such as referral through in-hospital specialists, may demonstrate longer or shorter delays.
Conclusion
Targeted strategies to reduce overall delay to treatment in RA rely on understanding where and why delay occurs in the context of the particular healthcare setting. This study confirms that, in Australia, delays in patient presentation to the GP for initial assessment contribute significantly to overall delay. More insidious disease onset (lower disease activity and fatigue scores) and greater socioeconomic disadvantage may result in more delayed presentation, suggesting that targeting disease awareness may be beneficial. Similarly, lower disease activity predicts greater delay in GP referral; however, non-specific features, including tender joints and raised ESR, may contribute to diagnostic uncertainty and predict greater delay. Treatment delay for RA in Australia remains significant despite strong evidence for the benefits of early treatment. A variety of strategies to promote earlier diagnosis of joint symptoms and early referral and to reduce delay should be considered. These Australian data will enable strategies and implementation to be tailored to the local setting to ensure timely care and optimal outcomes for people living with RA.
